Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for IgA Nephropathy Clinical Trials
IgA Nephropathy clinical trials are recruiting across 66 cities. Here are the cities with the most active studies:
IgA Nephropathy Trial Phases
11 research organizations are sponsoring iga nephropathy trials.
About IgA Nephropathy
IgA nephropathy is the most common form of glomerulonephritis worldwide, caused by deposits of immunoglobulin A in the kidneys. It can lead to kidney inflammation and progressive kidney damage. Treatment includes blood pressure management, immunosuppression, and newer targeted therapies.
Clinical trials are advancing new treatments for iga nephropathy. Currently, 15 studies are recruiting a combined 2,059 participants across the United States. Research is being conducted by 11 organizations including Biogen, Hoffmann-La Roche, Takeda and 8 others.
2026 IgA Nephropathy Research Landscape
As of July 2026, the iga nephropathy clinical trial landscape includes 15 actively recruiting studies across 66 cities in the United States. These studies are collectively seeking 2,059 participants, with an average enrollment target of 137 per study.
The research spans multiple phases of development: 6 studies are in PHASE3, 6 studies are in PHASE2, 2 studies are in PHASE1, 1 study is in PHASE4. The presence of Phase 3 trials indicates that some iga nephropathy treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 11 different organizations, including Biogen, Hoffmann-La Roche, Takeda, Novartis Pharmaceuticals, Calliditas Therapeutics AB, and 6 others. The large number of sponsors reflects significant research interest and investment in iga nephropathy treatment advancement.
Geographically, iga nephropathy trials are most concentrated in Los Angeles, California (4 trials); Birmingham, Alabama (4 trials); Orlando, Florida (4 trials); Miami, Florida (3 trials); Denver, Colorado (3 trials) and 7 other cities.
Featured IgA Nephropathy Studies
Highlighted recruiting studies for iga nephropathy, selected by enrollment size and research scope.
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much...
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein leve...
Frequently Asked Questions About IgA Nephropathy Clinical Trials
Are there iga nephropathy clinical trials near me?
Yes, there are 15 iga nephropathy clinical trials currently recruiting across 66+ cities in the United States, including Los Angeles, California; Birmingham, Alabama; Orlando, Florida. Browse the studies above to find one at a location convenient for you.
How do I join a iga nephropathy clinical trial?
To join a iga nephropathy clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are iga nephropathy clinical trials free?
Yes, participation in iga nephropathy clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of iga nephropathy treatments are being studied?
Current iga nephropathy clinical trials are testing a range of approaches across PHASE3 (6 studies), PHASE2 (6 studies), PHASE1 (2 studies), PHASE4 (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 11 research organizations.
Is it safe to participate in iga nephropathy clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 18, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 18, 2026 · Data from ClinicalTrials.gov